Amgen and Watson partnered to co-develop and commercialize biosimilars of cancer drugs Herceptin trastuzumab, Avastin bevacizumab, Rituxan rituximab and Erbitux cetuximab

Watson Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Amgen Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

$56,282.9m on 12/30/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced